StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

AnaptysBio's operating cash flow for the twelve months ending Jun 30, 2026 was $18.08M. For fiscal 2025 it was $19.70M. The highest annual figure on record is $19.70M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.70M–
FY2024Dec 31, 2024-$135.34M–
FY2023Dec 31, 2023-$120.80M–
FY2022Dec 31, 2022-$73.59M–
FY2021Dec 31, 2021-$45.92M–
FY2020Dec 31, 2020-$14.16M–
FY2019Dec 31, 2019-$69.52M–
FY2018Dec 31, 2018-$48.51M–
FY2017Dec 31, 2017-$19.44M–
FY2016Dec 31, 2016-$9.03M–
FY2015Dec 31, 2015-$9.69M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.64M–
Q1 FY2026Mar 31, 2026-$25.92M–
Q4 FY2025Dec 31, 2025$98.00M–
Q3 FY2025Sep 30, 2025-$27.36M–
Q2 FY2025Jun 30, 2025-$40.24M–
Q1 FY2025Mar 31, 2025-$10.70M–
Q4 FY2024Dec 31, 2024-$66.67M–
Q3 FY2024Sep 30, 2024-$10.09M–
Q2 FY2024Jun 30, 2024-$21.32M–
Q1 FY2024Mar 31, 2024-$37.25M–
Q4 FY2023Dec 31, 2023-$34.35M–
Q3 FY2023Sep 30, 2023-$36.47M–
Q2 FY2023Jun 30, 2023-$25.41M–
Q1 FY2023Mar 31, 2023-$24.57M–
Q4 FY2022Dec 31, 2022-$10.69M–
Q3 FY2022Sep 30, 2022-$17.75M–
Q2 FY2022Jun 30, 2022-$24.15M-351.8%
Q1 FY2022Mar 31, 2022-$21.01M–
Q4 FY2021Dec 31, 2021-$25.30M-167.3%
Q3 FY2021Sep 30, 2021-$7.01M–
Q2 FY2021Jun 30, 2021$9.59M–
Q1 FY2021Mar 31, 2021-$23.20M–
Q4 FY2020Dec 31, 2020$37.58M–
Q3 FY2020Sep 30, 2020-$17.01M–
Q2 FY2020Jun 30, 2020-$19.61M–
Q1 FY2020Mar 31, 2020-$15.11M–
Q4 FY2019Dec 31, 2019-$15.81M–
Q3 FY2019Sep 30, 2019-$22.10M–
Q2 FY2019Jun 30, 2019-$15.52M–
Q1 FY2019Mar 31, 2019-$16.10M–
Q4 FY2018Dec 31, 2018-$12.29M–
Q3 FY2018Sep 30, 2018-$14.86M–
Q2 FY2018Jun 30, 2018-$8.88M–
Q1 FY2018Mar 31, 2018-$12.48M–
Q4 FY2017Dec 31, 2017-$4.81M–
Q3 FY2017Sep 30, 2017-$3.89M–
Q2 FY2017Jun 30, 2017-$2.64M–
Q1 FY2017Mar 31, 2017-$8.10M–
Q4 FY2016Dec 31, 2016-$5.57M–
Q3 FY2016Sep 30, 2016-$3.07M–

More AnaptysBio figures

See a number that looks wrong?